




RealRate

PHARMACEUTICAL 2014

Whitehawk Therapeutics Inc
Rank 224 of 234



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Whitehawk Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Whitehawk Therapeutics Inc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 12% points. The greatest weakness of Whitehawk Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 177% points.

The company's Economic Capital Ratio, given in the ranking table, is 34%, being 209% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	133
Liabilities, Non-Current	0
Other Assets	8.8
Other Compr. Net Income	0
Other Expenses	5.9
Other Liabilities	0
Other Net Income	-23
Other Revenues	0
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	8.8
Liabilities	133
Expenses	5.9
Revenues	0
Stockholders Equity	-124
Net Income	-29
Comprehensive Net Income	-29
BaseVar	85
ECR before Limited Liability	-422%
Economic Capital Ratio	34%